Does circle priming improve smart infusion pump and electronic health record interoperability for chemotherapy in a pediatric hematology/oncology setting?
| Autor: | Agedal KJ; Department of Pharmacy, Upstate University Hospital, Syracuse, New York, USA., Steidl KE; Department of Pharmacy, Upstate University Hospital, Syracuse, New York, USA.; Department of Pediatrics, Upstate Medical University, Syracuse, New York, USA., Burgess JL; Department of Pharmacy, Upstate University Hospital, Syracuse, New York, USA., Seabury RW; Department of Pharmacy, Upstate University Hospital, Syracuse, New York, USA., Wojnowicz SR; Department of Pharmacy, Upstate University Hospital, Syracuse, New York, USA.; Department of Medicine, Upstate Medical University, Syracuse, New York, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2024 Jan; Vol. 30 (1), pp. 159-164. Date of Electronic Publication: 2023 Apr 19. |
| DOI: | 10.1177/10781552231170769 |
| Abstrakt: | Introduction: The objective of this project was to assess the percentage of interoperability compliance within our pediatric hematology/oncology patient care areas for intravenous chemotherapy medications before and after the implementation of circle priming. Methods: We conducted a retrospective quality improvement project at an inpatient pediatric hematology/oncology floor and outpatient pediatric infusion center before and after implementation of circle priming. Results: There was a statistically significant increase in percent interoperability compliance for the inpatient pediatric hematology/oncology floor from 4.1% prior to implementation of circle priming to 35.6% after (odds ratio 13.1 (95% CI, 3.96-43.1), p < 0.001), as well as for the outpatient pediatric infusion center from 18.5% to 47.3%, respectively (odds ratio 3.9 (95% CI, 2.7-5.9), p < 0.001). Conclusion: Implementation of circle priming has significantly increased the percentage of interoperability compliance for intravenous chemotherapy medications in our pediatric hematology/oncology patient care areas. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|